Oliceridine Versus Sufentanil for Postoperative Nausea in Cerebellopontine Angle Surgery
Recruiting
N/A
Interventional Study
PONV
Cerebellopontine Angle Tumor
Microvascular Decompression Surgery
Postoperative Analgesia
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 65
- Sex
- Any
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 174 (estimated)
- Sponsor
- Xuanwu Hospital, Beijing · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This single-center, double-blind, randomized controlled trial aims to determine whether oliceridine for patient-controlled intravenous analgesia (PCIA) can significantly reduce the incidence of postoperative nausea, an opioid-related adverse reaction, compared to sufentanil PCIA in patients undergoing cerebellopontine angle (CPA) region surgery. A secondary objective is to compare the postoperativ…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Scheduled for elective CPA region surgery with planned PCIA.
* Age 18-65 years.
* ASA physical status I-III.
* Provides written informed consent.
Exclusion Criteria:
* Opioid tolerance (taking opioids ≥1 week, equivalent to oral morphine ≥50 mg/day or oxycodone ≥30 mg/day).
…
Contacts